HKSE:2315

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 13:44 UTC

Last close

n/aHKD

Market data

82.2xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
21.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
12.6%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
20.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.27Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Price is the furthest below its sector's middle: 0.12 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Follow one yuan

lens 1 of 9

After what it costs to make

75.8%

After running the business

20.2%

After interest and tax

12.6%

After what it must reinvest

20.5%

Kept after the dividend

n/a

after what it costs to make, 75.8% of sales; after running the business, 20.2% of sales; after interest and tax, 12.6% of sales; after what it must reinvest, 20.5% of sales

The five stops

4 of 5 read

After what it costs to make1,045,590,00075.8%
After running the business278,599,00020.2%
After interest and tax173,199,00012.6%
After what it must reinvest282,433,00020.5%
Kept after the dividendn/an/a

The last stop is empty on purpose. This filing does not tag a common dividend, so what is kept after it cannot be worked out. That is not the same fact as a company that paid no dividend, and we will not print a zero for it.

What is left after the dividend is not held for this company.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales1,378,808,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
After what it costs to make1,045,590,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
After running the business278,599,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
After interest and tax173,199,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
After what it must reinvest282,433,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Kept after the dividendn/a
Not held.
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY